Company Description
MiniMed Group, Inc. operates as a medical technology company that develops, manufactures, and markets medical equipment for the management of diabetes.
The company offers technologies including insulin delivery devices, such as insulin pumps and pens, continuous glucose monitors, other consumables, supplies, and related software and services.
It serves people with diabetes who require insulin therapy, which represents all people with T1D and a subset of those with T2D.
The company’s platform includes Automated Insulin Delivery (AID) systems for glucose sensing and automated insulin dosing and administration for glycemic control and Smart Multiple Daily Injection (MDI) systems for self-administering insulin by manual injections, which include InPen, Simplera Sync, or Guardian 4 sensor, and wraparound applications and services.
It also offers CareLink, a software platform that provides support for person with diabetes, their caretakers, and HCPS.
MiniMed Group, Inc. was founded in 1983 and is headquartered in Northridge, California. MiniMed Group, Inc. operates as a subsidiary of Medtronic plc.
| Country | United States |
| Founded | 1983 |
| IPO Date | Mar 6, 2026 |
| Industry | Medical Instruments & Supplies |
| Sector | Healthcare |
| Employees | 8,000 |
| CEO | Que Dallara |
Contact Details
Address: 18000 Devonshire Street Northridge, California 91325 United States | |
| Phone | 763 514 4000 |
| Website | minimed.com |
Stock Details
| Ticker Symbol | MMED |
| Exchange | NASDAQ |
| Fiscal Year | May - April |
| Reporting Currency | USD |
| IPO Price | $20.00 |
| CIK Code | 2062583 |
| CUSIP Number | 60365F109 |
| ISIN Number | US60365F1093 |
| Employer ID | 33-3985981 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Que Thanh Dallara | Chief Executive Officer and Director |
| John Gyurci | Vice President, Chief Accounting Officer and Controller |
| Mike Bruggeman | SVice President and Chief Information Officer |
| Ryan Weispfenning | Head of Investor Relations |
| Kate Cronin MSN RN | SVice President and Chief Marketing Officer |
| Yael Glassman | SVice President, Chief Strategy and Corporate Development Officer |
| Slobodan Radumilo | SVice President and Chief Commercial Officer of EMEA and APAC |
| Muthu Sabarethinam | SVice President of Transformation and Analytics |
| Laura Endres | SVice President and Chief Commercial Officer of Americas |
| Robert A. Vigersky M.D. | Vice President and Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 1, 2026 | 8-K | Current Report |
| Aug 21, 2026 | ARS | Filing |
| Aug 21, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Aug 21, 2026 | DEF 14A | Other definitive proxy statements |
| Aug 5, 2026 | 8-K | Current Report |
| Jun 29, 2026 | 10-K | Annual Report |
| Jun 29, 2026 | 8-K | Current Report |
| Jun 3, 2026 | 8-K | Current Report |
| May 18, 2026 | 8-K | Current Report |
| May 6, 2026 | SCHEDULE 13G | Filing |